149 related articles for article (PubMed ID: 37987157)
1. Multi-cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma.
Yan J; Deng L; Yu J; Wu X; Wang S; Cang S
Clin Transl Med; 2023 Nov; 13(11):e1478. PubMed ID: 37987157
[No Abstract] [Full Text] [Related]
2. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
5. Vitreous metastasis from cutaneous melanoma while on checkpoint inhibitors.
Catapano TM; Bansal R; Shields CL
Asia Pac J Ophthalmol (Phila); 2024; 13(2):100050. PubMed ID: 38492668
[No Abstract] [Full Text] [Related]
6. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
7. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
[TBL] [Abstract][Full Text] [Related]
9.
Huang Y; Lin A; Gu T; Hou S; Yao J; Luo P; Zhang J
Immunotherapy; 2023 Oct; 15(15):1275-1291. PubMed ID: 37584225
[No Abstract] [Full Text] [Related]
10. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
11. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract][Full Text] [Related]
12. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.
Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G
Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
16. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
Front Immunol; 2021; 12():691032. PubMed ID: 34290710
[TBL] [Abstract][Full Text] [Related]
17. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
19. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract][Full Text] [Related]
20. A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy.
Pacaud A; Amintas S; Boussemart L; Cappellen D; Gérard E
Eur J Cancer; 2021 Apr; 147():161-163. PubMed ID: 33684875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
